Opinion|Videos|January 3, 2025
The Future of CAR-T: Advancing Myeloma Treatment Strategies
Panelists discuss the evolving role of chimeric antigen receptor T-cell therapy in earlier lines of treatment for multiple myeloma, with a focus on upcoming advances for patients with standard-risk disease and the impact of multidisciplinary collaboration on improving patient care and outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Dr Castaneda: Ask Jammie:
How do you see the role of chimeric antigen receptor (CAR) T-cell therapy evolving for earlier lines of treatment in multiple myeloma? What advances are you most excited about for patients with standard-risk disease?
Dr Castaneda: Ask Raja:
From your perspective, how has multidisciplinary collaboration in the use of CAR T-cell therapy improved patient care and outcomes?
Advertisement
Related to this article
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.
VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.
Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
4
How Would a TALAPRO-3 Approval Affect HRR-Altered Metastatic HSPC Care?
5